Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: Progress to date

Drugs

Volumn 70, Issue 3, 2010, Pages 241-259

  Becq, Frdric ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

Ataluren; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator modulators; Research and development; Therapeutic use; Treatment

Indexed keywords

15 DEOXYSPERGUALIN; 2622U90; 4 PHENYLBUTYRIC ACID; AMILORIDE; ATALUREN; BAY 399437; BENZAMIL; BENZOQUINONE DERIVATIVE; BORTEZOMIB; CAMOSAT MESYLATE; CORR4A; CURCUMIN; DENUFOSOL; DURAMYCIN; GELDANAMYCIN; GENTAMICIN; GUANABENZ ACETATE; HERBIMYCIN A; INO 4995; KM 11060; MIGLUSTAT; MPB 07; N BUTYLDEOXYGALACTONOJIRIMYCIN; QUA 145; SILDENAFIL; THAPSIGARGIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; VRT 325; VX 770; VX 809;

CLINICAL TRIAL; COST OF ILLNESS; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; FAMILY; GAUCHER DISEASE; GENE MUTATION; HEALTH CARE COST; HEALTH CARE FINANCING; HUMAN; LIFE EXPECTANCY; MOLECULAR CLONING; MORBIDITY; NONHUMAN; QUALITY OF LIFE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, BIOLOGICAL; MUTATION; PNEUMONIA;

EID: 77249176209     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11316160-000000000-00000     Document Type: Review

References (125)

1. Bobadilla JL, Macek Jr M, Fine JP, et al. Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 2002; 19: 575-606
2. Rommens JM, Iannuzzi MC, Kerem BS, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245: 1059-1065
3. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-1080 (Pubitemid 19231815)
4. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-1073 (Pubitemid 19231814)
5. Hanrahan JW, Gentzsch M, Riordan JR. The cystic fi-brosis transmembrane conductance regulator (ABCC7). In: Holland IB, Cole S, Kuchler K, et al., editors. ABC proteins: from bacteria to man. New York: Academic Press, 2003: 589-618
6. - channel in CHO cells stably expressing the cystic fibrosis gene. Nature 1991; 352: 628-631
7. Gadsby DC, Nairn AC. Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol Rev 1999; 79: 77-107
8. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352: 1992-2001 (Pubitemid 40638370)
9. Boucher RC. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 2007; 13: 231-240
10. Ribeiro CM. The role of intracellular calcium signals in inflammatory responses of polarised cystic fibrosis human airway epithelia. Drugs R D 2006; 7: 17-31
11. Jacquot J, Tabary O, Le Rouzic P, et al. Airway epithelial cell inflammatory signalling in cystic fibrosis. Int J Biochem Cell Biol 2008; 40: 1703-1715
12. Simmonds NJ, Cullinan P, Hodson ME. Growing old with cystic fibrosis: the characteristics of long-term survivors of cystic fibrosis. Res Med 2009; 103: 629-635
13. Rosenblatt RL. Lung transplantation in cystic fibrosis. Resp Care 2009; 54: 777-787
14. Castellani C, Cuppens H, Macek Jr M, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008; 7: 179-196
15. De Araujo FG, Novaes FC, Dos Santos NPC, et al. Pre-valence of DF508, G551D, G542X, and R553X mutations among cystic fibrosis patients in the north of Brazil. Braz J Med Biol Res 2005; 38: 11-15
16. Kabra SK, Kabra M, Lodha R, et al. Cystic fibrosis in India. Pediatr Pulmonol 2007; 42: 1087-1094
17. Scotet V, Gollet D, Dugueperoux I, et al. Spatial and temporal distribution of the cystic fibrosis and of its mutations in Brittany, France: a retrospective study from 1960. Hum Genet 2002; 111: 247-254
18. Dugueperoux I, De Braekeleer M. Genotype-phenotype relationship for five CFTR mutations frequently identified in western France. J Cyst Fibros 2004; 4: 259-263
19. First Eastern European Conference on the diagnosis of cystic fibrosis [online]. Available from URL: http://www. klinickagenetika.org [Accessed 2009 May 25]
20. Yamashiro Y, Shimizu T, Oguchi S, et al. The estimated in-cidence of cystic fibrosis in Japan. J Pediatr Gastroenterol Nutr 1997; 24: 544-547
21. Morrow BM, Argent AC, Zar HJ, et al. Improvements in lung function of a pediatric cystic fibrosis population in a developing country. J Pediatr (Rio J) 2008; 84: 403-409
22. Ratbi I, Genin E, Legendre M, et al. Cystic fibrosis carrier frequency and estimated prevalence of the disease in Morocco. J Cyst Fibros 2008; 7: 440-443
23. Cystic fibrosis genetic analysis consortium [online]. Avail-able from URL: http://www.genet.sickkid.on.ca/cftr [Accessed 2009 May 25]
24. Li N, Pei P, Bu D-F, et al. A novel CFTR mutation found in a Chinese patient with cystic fibrosis. Chin Med J 2006; 119: 103-109
25. Loumi O, Ferec C, Mercier B, et al. CFTR mutations in the Algerian population. J Cyst Fibros 2008; 7: 54-59
26. Messaoud T, Verlingue C, Denamur E, et al. Distribution of CFTR mutations in cystic fibrosis patients of Tunisian origin: identification of two novel mutations. Eur J Hum Genet 1996; 4: 20-24
27. Becq F. On the discovery and development of CFTR chloride channel activators. Curr Pharm Des 2006; 12: 471-484
28. Drumm ML, Wilkinson DJ, Smit LS, et al. Chloride con-ductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science 1991; 254: 1797-1799
29. Grubb B, Lazarowski E, Knowles M, et al. Isobutyl-methylxanthine fails to stimulate chloride secretion in cystic fibrosis airway epithelia. Am J Respir Cell Mol Biol 1993; 8: 454-460
30. Verkman AS. Drug discovery in academia. Am J Physiol 2004; 286: 465-474
31. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov 2009; 8: 153-171
32. Becq F. Pharmacological interventions for the correction of ion transport defect in cystic fibrosis. Expert Opin Ther Patents 2004; 14: 1465-1483
33. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73: 1251-1254
34. Cheng SH, Gregory RJ, Marshall J, et al. Defective in-tracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990; 63: 827-834
35. Dalemans W, Barbry P, Champigny G, et al. Altered chloride ion channel kinetics associated with the DF508 cystic fibrosis mutation. Nature 1991; 354: 526-528
36. Cutting GR, Kasch LM, Rosenstein BJ, et al. A cluster of cystic fibrosis mutations in the first nucleotide binding fold domain of the cystic fibrosis conductance regulator protein. Nature 1990; 346: 366-369
37. Becq F, Jensen TJ, Chang X-B, et al. Phosphatase in-hibitors activate normal and defective CFTR chloride channels. Proc Natl Acad Sci USA 1994; 91: 9160-9164
38. - channels with altered pore properties. Nature 1993; 362: 160-164
39. Haardt M, Benharouga M, Lechardeur D, et al. C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. J Biol Chem 1999; 31: 21873-21877
40. European Cystic Fibrosis Society [online]. Available from URL: http://www.ecfs.eu [Accessed 2009 May 25]
41. Cystic Fibrosis Foundation [online]. Available from URL: http://www.cff.org [Accessed 2009 May 25]
42. Doring G, Elborn JS, Johannesson M, et al. Clinical trials in cystic fibrosis. J Cyst Fibros 2007; 6: 85-99
43. Goss CH, Mayer-Hamblett N, Williams J, et al. The Cystic Fibrosis Foundation Therapeutics Development Network: a national effort by the Cystic Fibrosis Foundation to build a clinical trials network. Child Health Care 2008; 37: 5-20
44. Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997; 3: 1280-1284
45. Wilchanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349: 1433-1441
46. PTC Therapeutic [online]. Available from URL: http:// www.ptcbio.com [Accessed 2009 May 25]
47. Aurino S, Nigro V. Readthrough strategies for stop codons in Duchenne muscular dystrophy. Acta Myol 2006; 25: 5-12
48. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372: 719-727
49. Sermet-Gaudelus I, De Boeck K, Casimir G, et al. Children with nonsense-mutation-mediated cystic fibrosis respond to investigational treatment with PTC124 [abstract]. Pediatr Pulmonol 2008; Suppl. 31: 313
50. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995; 83: 122-127
51. Heda GD, Tanwani M, Marino CR. The delta F508 mu-tation shortens the biochemical half-life of plasma membrane CFTR in polarized epithelial cells. Am J Physiol Cell Physiol 2001; 280: 166-174
52. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmaco-logic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing DF508-CFTR. J Clin Invest 1997; 100: 2457-2465
53. Rubenstein RC, Zeitlin PL. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DF508-CFTR. Am J Physiol 2000; 278: 259-267
54. Choo-Kang LR, Zeitlin PL. Induction of HSP70 promotes deltaF508 CFTR trafficking. Am J Physiol 2001; 281: L58-68
55. Egan ME, Glockner-Pagel J, Ambrose CA, et al. Calcium-pump inhibitors induce functional surface expression of DF508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 2002; 8: 485-492
56. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004; 304: 600-602
57. 2+ level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells. Traffic 2006; 7: 562-573
58. Dormer RL, Harris CM, Clark Z, et al. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005; 60: 55-59
59. Lubamba B, Lecourt H, Lebacq J, et al. Preclinical evi-dence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008; 177: 506-515
60. Poschet JF, Timmins GS, Taylor-Cousar JL, et al. Pharmacological modulation of cGMP levels by phos-phodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 293: 712-719
61. Robert R, Carlile GW, Pavel C, et al. Structural analogue of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharm 2008; 73: 478-489
62. Becq F, Zegarra-Moran O. Specific pharmacological ther-apy in cystic fibrosis. Workpackage 5: novel therapies [online]. Available from URL: http://www.eurocarecf.eu/ [Accessed 2009 May 25]
63. Van Goor F, Straley KS, Cao D, et al. Rescue of DF508 CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290: 1117-1130
64. Vertex Pharmaceuticals [online]. Available from URL: http://www.vpharm. com [Accessed 2009 May 25]
65. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115: 2564-2571
66. Actelion Pharmaceuticals [online]. Available from URL: http://www.actelion.com [Accessed 2009 May 25]
67. McCormack PL, Goa KL. Miglustat. Drugs 2003; 63: 2427-2434
68. Dwek RA, Butters TD, Platt FM, et al. Targeting glyco-sylation as a therapeutic approach. Nat Rev Drug Discov 2002; 1: 65-75
69. Ficicioglu C. Review of miglustat for clinical management in Gaucher disease type I. Ther Clin Risk Manag 2008; 4: 425-431
70. Norez C, Noel S, Wilke M, et al. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the a-glucosidase inhibitor miglustat. FEBS Lett 2006; 580: 2081-2086
71. Noel S, Wilke M, Bot A, et al. Parallel improvement of sodium and chloride transport defects by miglustat in cystic fibrosis epithelial cells. J Pharmacol Exp Ther 2008; 325: 1016-1023
72. Norez C, Antigny F, Noel S, et al. A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis-like phenotype. Am J Respir Cell Mol Biol 2009; 41: 217-225
73. Lubamba B, Lebacq J, Lebecque P, et al. Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med 2009; 179 (11): 1022-1028
74. Antigny F, Norez C, Becq F, et al. Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR. Cell Calcium 2008; 43: 175-183
75. Dechecchi MC, Nicolis E, Norez C, et al. Anti-inflam-matory effect of miglustat in bronchial epithelial cells. J Cyst Fibros 2008; 7: 555-565
76. Pedemonte N, Sondo E, Caputo A, et al. Dual activity of aminoarylthiazoles on trafficking and gating defects caused by CF mutations [abstract]. Pediatr Pulmonol 2008; Suppl. 31: 311
77. Norez C, Bilan F, Kitzis A, et al. Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622. J Pharmacol Exp Ther 2008; 325: 89-99
78. Becq F, Mettey Y, Gray MA, et al. Development of sub-stituted benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel. J Biol Chem 1999; 274: 27415-27425
79. Marivingt-Mounir C, Norez C, Derand R, et al. Synthesis, SAR, crystal structure, and biological evaluation of ben-zoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels. J Med Chem 2004; 47: 962-972
80. Dormer RL, Derand R, McNeilly C, et al. Correction of delF508-CFTR activity with benzoquinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. J Cell Sci 2001; 114: 4073-4081
81. Derand R, Bulteau-Pignoux L, Mettey Y, et al. Activation of G551D CFTR channel with MPB-91: regulation by ATPase activity and phosphorylation. Am J Physiol Cell Physiol 2001; 281: 1657-1666
82. Stratford FLL, Pereira MMC, Becq F, et al. Benzo(c)qui-nolizinium drugs inhibit degradation of DF508-CFTR cytoplasmic domain. Biochem Bioph Res Com 2003; 300: 524-530
83. Young A, Gentzsch M, Abban CY, et al. Dynasore inhibits removal of wild-type and DeltaF508 CFTR from the plasma membrane. Biochem J 2009 Jul 15; 421 (3): 377-385
84. Loo MA, Jensen TJ, Cui L, et al. Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. EMBO J 1998; 17: 6879-6887
85. Vij N, Fang S, Zeitlin PL. Selective inhibition of endo-plasmic reticulum-associated degradation rescues Del-taF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J Biol Chem 2006; 281: 17369-17378
86. Bortezomib information [online]. Available from URL: http://www. bortezomib.org [Accessed 2009 May 25]
87. Jiang C, Fang SL, Xiao YF, et al. Partial restoration of cAMP-stimulated CFTR chloride channel activity in DeltaF508 cells by deoxyspergualin. Am J Physiol 1998; 275: C171-8
88. - channel functions. Am J Physiol Lung Cell Mol Physiol 2008; 295: L336-47
89. Pedemonte N, Sonawane ND, Taddei A, et al. Phenylgly-cine and sulfonamide correctors of defective DF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005; 67: 1797-1807 (Pubitemid 40594181)
90. Sammelson RE, Ma T, Galietta LJV, et al. 3-(2-benzy-phenyl)isoxazoles and isoxazolines: synthesis and evaluation as CFTR activators. Bio Med Chem Lett 2003; 13: 2509-2512
91. Ma T, Vetrivel L, Yang H, et al. High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol Chem 2002; 277: 37235-37241
92. Accurso FJ, Rowe SM, Durie PR, et al. Interim results of Phase 2A study of VX770 to evaluate safety, pharmaco-kinetics, and biomarkers of CFTR activity in cystic fi-brosis subjects with G551D [abstract]. Pediatr Pulmonol 2008; Suppl. 31: 295
93. Noel S, Faveau C, Norez C, et al. Discovery of pyrrolo[2,3-b]pyrazines derivatives as submicromolar affinity activators of wild-type, G551D and F508del CFTR chloride channels. J Pharmacol Exp Ther 2006; 319: 349-359
94. Hofmann T, Senier I, Bittner P, et al. Aerosolized amilor-ide: dose effect on nasal bioelectric properties, pharma-cokinetics, and effect on sputum expectoration in patients with cystic fibrosis. J Aerosol Med 1997; 10: 147-158
95. Hofmann T, Stutts MJ, Ziersch A, et al. Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis. Am JRespir Crit Care Med 1998; 157: 1844-1849
96. Graham A, Hasani A, Alton EW, et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993; 6: 1243-1248
97. Pons G, Marchand MC, D'Athis P, et al. French multi-center randomised double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. Pediatr Pulmonol 2000; 30: 25-31
98. Rodgers HC, Knox AJ. The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis. Eur J Respir 1999; 14: 693-696
99. Parion Sciences [online]. Available from URL: http://www. parion.com [Accessed 2009 May 25]
100. Hirsh AJ, Zhang J, Zamurs A, et al. Pharmacological prop-erties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy) phenyl]butyl-guanidine metha-nesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2008; 325: 77-88
101. + channel by peptidases. Curr Top Dev Biol 2007; 78: 23-46
102. + transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437. Am J Physiol 2001; 281: 16-23
103. Clinicaltrials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2009 May 25]
104. Rowe SM, Reeves G, Young H, et al. Correction of sodium transport with nasal administration of the prostasin inhibitor QUA145 in CF subjects [abstract]. Pediatr Pul-monol 2008; Suppl. 31: 295
105. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (biphenyl) in DF508-homo-zygous cystic fibrosis patients. Am J Respir Crit Care Med 1998; 157: 484-490
106. Hwang TH, Schwiebert EM, Guggino WB. Apical and basolateral ATP stimulates tracheal epithelial chloride secretion via multiple purinergic receptors. Am J Physiol 1996; 270: C1611-23
107. Kellerman D, Mospan AR, Engens J, et al. Denofosol: a review of studies with inhaled P2Y2 agonists that led to phase 3. Pulm Pharm Ther 2008; 21: 600-607
108. Inspire Pharmaceuticals [online]. Available from URL: http://www.inspirepharm.com [Accessed 2009 May 25]
109. ISM Therapeutics [online]. Available from URL: http:// www.ismtherapeutics.com [Accessed 2009 May 25]
110. Rudolf MT, Dinkel C, Traynor-Kaplan AE, et al. An-tagonists of myo-Inositol 3,4,5,6-tetrakisphophate allow repeated epithelial chloride secretion. Bioorg Med Chem 2003; 11: 3315-3329
111. + transport and im-proves fluid dynamics in cystic fibrosis airway epithelia. Am J Physiol 2005; 289: C512-20
112. Traynor-Kaplan AE, Moody M, Nur M, et al. INO-4995 therapeutic efficacy is enhanced with repeat dosing in cystic fibrosis knockout mice and human epithelia. Am J Respir Cell Mol Biol 2010; 42 (1): 105-112
113. Grasemann H, Stehling F, Brunar H, et al. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 2007; 131: 1461-1466
114. Cloutier MM, Guernsey L, Sha'afi RI. Duramycin in-creases intracellular calcium in airway epithelium. Membr Biochem 1993; 10: 107-118
115. Zeitlin PL, Boyle MP, Guggino WB, et al. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 2004; 125: 143-149
116. AOP Orphan Pharmaceuticals AG [online]. Available from URL: http://www.aoporphan.com/ [Accessed 2009 May 25]
117. 2+-de-pendent chloride currents in cystic fibrosis human airway epithelial cells. Eur J Pharmacol 2008; 592: 33-40
118. Holmes B, Brogden RN, Hell RC, et al. Guanabenz: a re-view of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 1983; 26: 212-229
119. Perez A, Issler AC, Cotton CU, et al. CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 2007; 292: 383-395
120. Dechecchi MC, Nicolis E, Bezzerri V, et al. MPB-07 re-duces the inflammatory response to Pseudomonas aeru-ginosa in cystic fibrosis bronchial cells. Am J Respir Cell Mol Biol 2007; 36: 615-624
121. Talebian L, Coutermarsh B, Channon JY, et al. Corr4a and VRT325 do not reduce the inflammatory response to P. Aeruginosa in human cystic fibrosis airway epithelial cells. Cell Physiol Biochem 2009; 23: 199-204
122. Eidelman O, Guay-Broder C, Van Galen PJM, et al. A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc Natl Acad Sci USA 1992; 89: 5562-5566
123. Srivastava M, Eidelman O, Zhang J, et al. Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. Proc Natl Acad Sci USA 2004; 101: 7693-7698
124. Bernard C. Introduction a l'etude de la medecine expri-mentale. Paris: JB Bailliere et Fils, 1865.
125. Schultz SG. A century of (epithelial) transport physiology: from vitalism to molecular cloning. Am J Physiol 1998; 274: C12-23